RU2143919C1 - Фармацевтическая композиция, продукт трансэтерификации кукурузного масла глицерином и способ его получения - Google Patents
Фармацевтическая композиция, продукт трансэтерификации кукурузного масла глицерином и способ его получения Download PDFInfo
- Publication number
- RU2143919C1 RU2143919C1 SU5052126/A SU5052126A RU2143919C1 RU 2143919 C1 RU2143919 C1 RU 2143919C1 SU 5052126/A SU5052126/A SU 5052126/A SU 5052126 A SU5052126 A SU 5052126A RU 2143919 C1 RU2143919 C1 RU 2143919C1
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- cyclosporin
- product
- phase
- Prior art date
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title claims abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 52
- 235000005687 corn oil Nutrition 0.000 title claims abstract description 27
- 239000002285 corn oil Substances 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000005809 transesterification reaction Methods 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 101
- 229960001265 ciclosporin Drugs 0.000 claims abstract description 68
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 63
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 63
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 62
- 239000012071 phase Substances 0.000 claims abstract description 60
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 45
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 36
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 34
- 239000004094 surface-active agent Substances 0.000 claims abstract description 20
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 18
- 239000002253 acid Substances 0.000 claims abstract description 16
- 239000000194 fatty acid Substances 0.000 claims abstract description 15
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 13
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 12
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 12
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 12
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 11
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 9
- 230000008014 freezing Effects 0.000 claims abstract description 8
- 238000007710 freezing Methods 0.000 claims abstract description 8
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 238000007670 refining Methods 0.000 claims abstract description 5
- 239000003054 catalyst Substances 0.000 claims abstract description 4
- 239000007790 solid phase Substances 0.000 claims abstract description 3
- 235000011187 glycerol Nutrition 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 229960004063 propylene glycol Drugs 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 235000021313 oleic acid Nutrition 0.000 claims description 13
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 150000002889 oleic acids Chemical class 0.000 claims description 10
- 239000007903 gelatin capsule Substances 0.000 claims description 9
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 9
- 239000008158 vegetable oil Substances 0.000 claims description 9
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 8
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 6
- 240000008042 Zea mays Species 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 238000005191 phase separation Methods 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims description 3
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims description 3
- 108010019249 cyclosporin G Proteins 0.000 claims description 3
- 230000003993 interaction Effects 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 125000005481 linolenic acid group Chemical group 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 7
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- 239000008117 stearic acid Substances 0.000 abstract description 5
- 230000007423 decrease Effects 0.000 abstract description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract description 3
- 239000005642 Oleic acid Substances 0.000 abstract description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 2
- 238000010257 thawing Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- -1 linolinic Chemical class 0.000 description 7
- 238000007127 saponification reaction Methods 0.000 description 7
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 235000009973 maize Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008389 polyethoxylated castor oil Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
- WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 108010036941 Cyclosporins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- OURWLMNRUGYRSC-UHFFFAOYSA-N 12-(1-hydroxypropan-2-yloxy)octadecanoic acid Chemical compound CCCCCCC(OC(C)CO)CCCCCCCCCCC(O)=O OURWLMNRUGYRSC-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000796533 Arna Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- WMNULTDOANGXRT-UHFFFAOYSA-N bis(2-ethylhexyl) butanedioate Chemical compound CCCCC(CC)COC(=O)CCC(=O)OCC(CC)CCCC WMNULTDOANGXRT-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 235000021149 fatty food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002103 osmometry Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/04—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils
- C11C3/06—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fats or fatty oils with glycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medical Informatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919113872A GB9113872D0 (en) | 1991-06-27 | 1991-06-27 | Improvements in or relating to organic compounds |
| GB9113872,7 | 1991-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2143919C1 true RU2143919C1 (ru) | 2000-01-10 |
Family
ID=10697415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU5052126/A RU2143919C1 (ru) | 1991-06-27 | 1992-06-26 | Фармацевтическая композиция, продукт трансэтерификации кукурузного масла глицерином и способ его получения |
Country Status (38)
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2289251C2 (ru) * | 2000-08-03 | 2006-12-20 | Даниско А/С | Твердофазный глицеролиз |
| RU2462876C2 (ru) * | 2007-02-14 | 2012-10-10 | Сила С.Р.Л. | Продукт на основе конъюгированной линолевой кислоты и способ его получения |
| US8518961B2 (en) | 2004-11-19 | 2013-08-27 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical compositions comprising a camptothecin derivate |
| RU2639482C2 (ru) * | 2010-12-13 | 2017-12-21 | Новартис Аг | Фармацевтические композиции |
| RU2810897C2 (ru) * | 2018-11-26 | 2023-12-29 | Гепион Фармасьютикалс, Инк. | Фармацевтические составы аналогов циклоспорина |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
| PT589843E (pt) | 1992-09-25 | 2002-04-29 | Novartis Ag | Composicoes farmaceuticas contendo ciclosporinas |
| NZ247516A (en) * | 1993-04-28 | 1995-02-24 | Bernard Charles Sherman | Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant |
| GB2278780B (en) * | 1993-05-27 | 1998-10-14 | Sandoz Ltd | Macrolide formulations |
| AT408520B (de) * | 1993-05-27 | 2001-12-27 | Novartis Erfind Verwalt Gmbh | Galenische formulierungen |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
| SI0649651T1 (en) * | 1993-09-28 | 2001-02-28 | Scherer Gmbh R P | Soft gelatin capsule manufacture |
| DE4340781C3 (de) * | 1993-11-30 | 2000-01-27 | Novartis Ag | Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung |
| US5891846A (en) * | 1994-02-17 | 1999-04-06 | Shiseido Company, Ltd. | Cyclosporin-containing emulsion composition |
| WO1995022343A1 (en) * | 1994-02-17 | 1995-08-24 | Shiseido Company, Ltd. | Cyclosporin-containing emulsion composition |
| NZ270145A (en) * | 1994-03-01 | 1996-08-27 | Lilly Co Eli | Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| DE69510404T2 (de) * | 1994-03-31 | 2000-01-20 | Loders Croklaan B.V., Wormerveer | Öle mit niedrigem Gehalt an gesättigter Fettsäure |
| GB2308545B (en) * | 1994-10-26 | 1999-06-02 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| PE52896A1 (es) | 1994-10-26 | 1996-12-12 | Novartis Ag | Composicion farmaceutica |
| JP3833248B2 (ja) | 1994-11-03 | 2006-10-11 | ノバルティス・アクチエンゲゼルシャフト | 簡単な組成及び高い生物有効性を有する経口投与のためのシクロスポリンの新規処方物及びその製造法 |
| HU215966B (hu) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum |
| US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| WO1996036330A2 (en) * | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Compositions containing fatty acids for improving digestion and absorption in the small intestine |
| JPH11505258A (ja) * | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US6008228A (en) * | 1995-06-06 | 1999-12-28 | Hoffman-La Roche Inc. | Pharmaceutical compositions containing proteinase inhibitors |
| US6696413B2 (en) * | 1995-06-16 | 2004-02-24 | Hexal Ag | Pharmaceutical preparation with cyclosporin A |
| SE504582C2 (sv) * | 1995-07-06 | 1997-03-10 | Gs Dev Ab | Cyklosporinkomposition baserad på en L2-fas |
| DE19549852B4 (de) * | 1995-11-29 | 2009-06-04 | Novartis Ag | Cyclosporin enthaltende Präparate |
| US5858401A (en) * | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| CN1104258C (zh) * | 1996-05-29 | 2003-04-02 | 周德和 | 用于环孢霉素a的赋形剂 |
| US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
| ATE392891T1 (de) * | 1996-06-19 | 2008-05-15 | Novartis Pharma Gmbh | Cyclosporin enthaltende präparate |
| KR980008239A (ko) * | 1996-07-26 | 1998-04-30 | 김충환 | 사이클로스포린-함유 약학적 조성물 |
| FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| US6517860B1 (en) | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| WO1999027946A1 (en) * | 1997-12-02 | 1999-06-10 | Chong Kun Dang Corp. | Pharmaceutical composition comprising cyclosporin solid-state microemulsion |
| BR9808656A (pt) * | 1997-03-12 | 2000-05-23 | Abbott Lab | Sistemas binários hidrofìlicos para a administração de ciclosporina |
| NZ314702A (en) * | 1997-04-29 | 1998-07-28 | Bernard Charles Sherman | Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent |
| AR012627A1 (es) | 1997-04-29 | 2000-11-08 | Sherman Bernard Charles | Pre-concentrado de emulsion que comprende una ciclosporina y monoglicerido acetilado |
| GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
| DE69808463T2 (de) | 1997-07-29 | 2003-06-26 | Pharmacia & Upjohn Co., Kalamazoo | Selbstemulgierende formulierung enthaltend saure lipophile verbindungen |
| SI0999826T1 (en) * | 1997-07-29 | 2004-12-31 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
| SK284579B6 (sk) | 1997-07-29 | 2005-07-01 | Pharmacia & Upjohn Company | Farmaceutická kompozícia pre lipofilné zlúčeniny |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| US6657104B1 (en) | 1997-10-16 | 2003-12-02 | Texas Systems, University Of The Board Of The Regents | Transgenic mouse model for cardiac hypertrophy and methods of use thereof |
| ATE497384T1 (de) | 1997-12-10 | 2011-02-15 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
| PT982035E (pt) * | 1998-08-18 | 2004-08-31 | Panacea Biotec Ltd | Composicao de ciclosporina compreendendo um veiculo hidrofilo |
| WO2000033862A1 (en) * | 1998-12-11 | 2000-06-15 | Pharmasolutions, Inc. | Self-emulsifying compositions for drugs poorly soluble in water |
| EP1154759B1 (en) | 1998-12-30 | 2008-08-13 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
| GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| CN1167462C (zh) * | 1999-03-09 | 2004-09-22 | 杭州华东医药集团生物工程研究所有限公司 | 一种含环孢素的药物组合物 |
| US6956048B2 (en) | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
| AU2127400A (en) * | 1999-11-02 | 2001-05-14 | Cipla Limited | A pharmaceutical composition for the administration of water-insoluble pharmaceutically active substances and process for preparation thereof |
| US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| GB0008785D0 (en) | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| EP1430783B1 (en) * | 2000-08-08 | 2006-10-11 | Kao Corporation | Oil/fat composition |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| AR033711A1 (es) * | 2001-05-09 | 2004-01-07 | Novartis Ag | Composiciones farmaceuticas |
| PL210841B1 (pl) | 2001-10-19 | 2012-03-30 | Isotechnika Inc | Sposób wytwarzania mieszaniny izomerów (E) i (Z) ISATX247 |
| EP1435910B9 (en) | 2001-10-19 | 2010-02-03 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| KR100441167B1 (ko) * | 2001-12-27 | 2004-07-21 | 씨제이 주식회사 | 마이크로에멀젼 예비 농축액 조성물 |
| KR100525234B1 (ko) * | 2003-02-19 | 2005-10-28 | 한국유나이티드제약 주식회사 | 사이클로스포린 함유 연질캅셀제 및 그 제조방법 |
| GB0504950D0 (en) | 2005-03-10 | 2005-04-20 | Novartis Ag | Organic compositions |
| JP4889262B2 (ja) * | 2005-08-19 | 2012-03-07 | 理研ビタミン株式会社 | 脂溶性薬剤組成物 |
| MD3347G2 (ro) * | 2006-12-26 | 2008-01-31 | Институт Сельскохозяйственной Техники "Mecagro" | Procedeu de obţinere a esterilor metilici din ulei de rapiţă |
| CN101990429A (zh) | 2007-04-04 | 2011-03-23 | 希格默伊德药业有限公司 | 一种口服药物组合物 |
| CN101199836B (zh) * | 2007-11-07 | 2011-03-30 | 安徽省药物研究所 | 一种阶段释放型环孢素a固体微乳制剂及其微乳固化方法 |
| CA2762179A1 (en) | 2009-05-18 | 2010-11-25 | Sigmoid Pharma Limited | Composition comprising oil drops |
| WO2011018504A2 (en) | 2009-08-12 | 2011-02-17 | Sigmoid Pharma Limited | Immunomodulatory compositions comprising a polymer matrix and an oil phase |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| FR2971941B1 (fr) | 2011-02-24 | 2013-08-02 | Physica Pharma | Compositions pharmaceutiques administrables par voie cutanee et destinees au traitement local de la dermatite atopique canine |
| GB201304662D0 (en) | 2013-03-14 | 2013-05-01 | Sigmoid Pharma Ltd | Compositions |
| EA036036B1 (ru) | 2014-11-07 | 2020-09-16 | Сигмойд Фарма Лимитед | Композиции, содержащие циклоспорин |
| JPWO2020050182A1 (ja) * | 2018-09-06 | 2020-09-10 | 株式会社カマタ | カプセル充填用液状組成物及びカプセル剤 |
| FI3886813T3 (fi) * | 2018-11-26 | 2023-05-04 | Hepion Pharmaceuticals Inc | Syklosporiinianalogien farmaseuttisia formulaatioita |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2711470A1 (de) * | 1976-03-17 | 1977-09-22 | Gattefosse Ets Sa | Glyceridmischung, verfahren zu ihrer herstellung und ihre verwendung |
| US4652406A (en) * | 1984-12-08 | 1987-03-24 | Henkel Kommanditgesellschaft Auf Aktien | Process for the production of fatty acid alkyl esters |
| FR2685706A1 (fr) * | 1991-06-27 | 1993-07-02 | Sandoz Sa | Produit de transesterification de l'huile de mauis avec le glycerol et sa preparation. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1274354A (fr) * | 1956-03-10 | 1961-10-27 | Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol | |
| FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
| CH641356A5 (en) * | 1979-02-27 | 1984-02-29 | Sandoz Ag | Pharmaceutical compositions containing cyclosporin |
| BE895724A (fr) * | 1982-02-01 | 1983-07-28 | Sandoz Sa | Nouvelle utilisation therapeutique de la dihydrocyclosporine d |
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JPS62201591A (ja) * | 1986-02-28 | 1987-09-05 | Shoichi Shimizu | 油脂のグリセロリシス法 |
| JP2632010B2 (ja) * | 1988-01-29 | 1997-07-16 | 三共株式会社 | シクロスポリン製剤 |
| CH679119A5 (enExample) * | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
| HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| GB8823621D0 (en) * | 1988-10-07 | 1988-11-16 | Madhok R | Compositions containing cyclosporins |
| JPH0738771B2 (ja) * | 1989-01-17 | 1995-05-01 | 花王株式会社 | 液状食用油組成物 |
| BE1003009A5 (fr) * | 1989-02-09 | 1991-10-22 | Sandoz Sa | Nouvelles compositions pharmaceutiques a base de cyclosporines. |
| AU6785490A (en) * | 1989-12-18 | 1991-06-20 | Kraft General Foods, Inc. | Low-saturate edible oils and transesterification methods for production thereof |
-
1991
- 1991-06-27 GB GB919113872A patent/GB9113872D0/en active Pending
-
1992
- 1992-06-12 HU HU9201975A patent/HU216792B/hu unknown
- 1992-06-15 DE DE4244986A patent/DE4244986B4/de not_active Expired - Lifetime
- 1992-06-15 DE DE4244930A patent/DE4244930C2/de not_active Expired - Lifetime
- 1992-06-15 DE DE4219526A patent/DE4219526C2/de not_active Expired - Lifetime
- 1992-06-23 CH CH1971/92A patent/CH684163A5/de not_active IP Right Cessation
- 1992-06-23 IT ITRM920476A patent/IT1254401B/it active
- 1992-06-23 ES ES99106122T patent/ES2227921T3/es not_active Expired - Lifetime
- 1992-06-23 PT PT92810479T patent/PT539319E/pt unknown
- 1992-06-23 ES ES92810479T patent/ES2142818T3/es not_active Expired - Lifetime
- 1992-06-23 EP EP99106122A patent/EP0953630B1/en not_active Expired - Lifetime
- 1992-06-23 DK DK99106122T patent/DK0953630T3/da active
- 1992-06-23 EP EP92810479A patent/EP0539319B1/en not_active Expired - Lifetime
- 1992-06-23 PT PT99106122T patent/PT953630E/pt unknown
- 1992-06-23 DK DK92810479T patent/DK0539319T3/da active
- 1992-06-23 CH CH296/94A patent/CH685764A5/de not_active IP Right Cessation
- 1992-06-24 CY CY190692A patent/CY1906A/en unknown
- 1992-06-24 FR FR9207856A patent/FR2678169B1/fr not_active Expired - Lifetime
- 1992-06-24 GB GB9213393A patent/GB2257359B/en not_active Expired - Lifetime
- 1992-06-24 MX MX9203236A patent/MX9203236A/es unknown
- 1992-06-25 AU AU18527/92A patent/AU659460B2/en not_active Expired
- 1992-06-25 NZ NZ243309A patent/NZ243309A/en not_active IP Right Cessation
- 1992-06-25 AT AT0129892A patent/AT403436B/de not_active IP Right Cessation
- 1992-06-25 MY MYPI92001199A patent/MY109512A/en unknown
- 1992-06-25 IL IL11854692A patent/IL118546A/en not_active IP Right Cessation
- 1992-06-25 FI FI922958A patent/FI109454B/fi not_active IP Right Cessation
- 1992-06-25 LU LU88138A patent/LU88138A1/fr unknown
- 1992-06-25 CZ CS921977A patent/CZ281790B6/cs not_active IP Right Cessation
- 1992-06-25 ZA ZA924719A patent/ZA924719B/xx unknown
- 1992-06-25 NO NO922506A patent/NO303964B1/no not_active IP Right Cessation
- 1992-06-25 SK SK1977-92A patent/SK278759B6/sk not_active IP Right Cessation
- 1992-06-25 PH PH44558A patent/PH30337A/en unknown
- 1992-06-25 IL IL102310A patent/IL102310A/xx not_active IP Right Cessation
- 1992-06-26 RU SU5052126/A patent/RU2143919C1/ru active
- 1992-06-26 RO RO92-0868A patent/RO111021B1/ro unknown
- 1992-06-26 CA CA002072509A patent/CA2072509C/en not_active Expired - Lifetime
- 1992-06-26 KR KR1019920011198A patent/KR0131064B1/ko not_active Expired - Lifetime
- 1992-06-26 CA CA002175842A patent/CA2175842C/en not_active Expired - Lifetime
- 1992-06-26 JP JP4168946A patent/JP2653958B2/ja not_active Expired - Lifetime
- 1992-06-29 TW TW081105112A patent/TW267943B/zh not_active IP Right Cessation
- 1992-07-01 IE IE922082A patent/IE73662B1/en not_active IP Right Cessation
- 1992-10-31 SA SA92130213A patent/SA92130213B1/ar unknown
-
1993
- 1993-01-01 CN CN93100563A patent/CN1077798C/zh not_active Expired - Lifetime
- 1993-02-01 FR FR9301141A patent/FR2685706A1/fr active Granted
- 1993-06-18 UA UA93003147A patent/UA35559C2/uk unknown
-
1994
- 1994-11-09 EE EE9400190A patent/EE03108B1/xx unknown
- 1994-11-30 UY UY23864A patent/UY23864A1/es not_active IP Right Cessation
-
1995
- 1995-06-14 RO RO95-01142A patent/RO111110B1/ro unknown
-
1996
- 1996-04-03 HK HK57196A patent/HK57196A/xx not_active IP Right Cessation
- 1996-04-03 FI FI961513A patent/FI116199B/fi not_active IP Right Cessation
- 1996-06-03 IL IL11854696A patent/IL118546A0/xx unknown
- 1996-08-22 HK HK157696A patent/HK157696A/xx not_active IP Right Cessation
- 1996-09-12 JP JP24170596A patent/JP3420897B2/ja not_active Expired - Lifetime
- 1996-10-15 NO NO19964382A patent/NO325267B1/no not_active IP Right Cessation
-
1997
- 1997-06-20 KR KR1019970026005A patent/KR100231385B1/ko not_active Expired - Lifetime
-
1998
- 1998-09-22 KR KR1019980039160A patent/KR100231384B1/ko not_active Expired - Lifetime
-
2000
- 2000-01-14 GR GR20000400064T patent/GR3032366T3/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2711470A1 (de) * | 1976-03-17 | 1977-09-22 | Gattefosse Ets Sa | Glyceridmischung, verfahren zu ihrer herstellung und ihre verwendung |
| US4652406A (en) * | 1984-12-08 | 1987-03-24 | Henkel Kommanditgesellschaft Auf Aktien | Process for the production of fatty acid alkyl esters |
| FR2685706A1 (fr) * | 1991-06-27 | 1993-07-02 | Sandoz Sa | Produit de transesterification de l'huile de mauis avec le glycerol et sa preparation. |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2289251C2 (ru) * | 2000-08-03 | 2006-12-20 | Даниско А/С | Твердофазный глицеролиз |
| US8518961B2 (en) | 2004-11-19 | 2013-08-27 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical compositions comprising a camptothecin derivate |
| RU2620331C2 (ru) * | 2004-11-19 | 2017-05-24 | Сигма-Тау Индустрие Фармачеутике Рьюните С.П.А. | Фармацевтические композиции, включающие производное камптотецина |
| RU2462876C2 (ru) * | 2007-02-14 | 2012-10-10 | Сила С.Р.Л. | Продукт на основе конъюгированной линолевой кислоты и способ его получения |
| RU2639482C2 (ru) * | 2010-12-13 | 2017-12-21 | Новартис Аг | Фармацевтические композиции |
| RU2810897C2 (ru) * | 2018-11-26 | 2023-12-29 | Гепион Фармасьютикалс, Инк. | Фармацевтические составы аналогов циклоспорина |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2143919C1 (ru) | Фармацевтическая композиция, продукт трансэтерификации кукурузного масла глицерином и способ его получения | |
| EP0589843B1 (en) | Pharmaceutical compositions containing cyclosporins | |
| JP2818298B2 (ja) | サイクロスポリン誘導体含有医薬組成物 | |
| US6258808B1 (en) | Pharmaceutical composition | |
| EP1109532B1 (en) | Oral micro-emulsion composition of silybin | |
| HU225535B1 (en) | Microemulsion pre-concentrate and microemulsion | |
| CY1958A (en) | Transesterified corn oil products | |
| MXPA99008438A (en) | Pharmaceutical compositions |